Quantum Genesis AI Corp
quantumzymecorp.comWhat Do They Do?
Develops engineered enzymes for pharmaceutical companies making active pharmaceutical ingredients, starting with an enzyme for ibuprofen production.
10-K for FY2025, filed Nov 13, 2025
Who Are Their Customers?
Targets select pharmaceutical companies that produce generic drugs and is identifying third-party manufacturers and distributors to make and distribute its enzyme.
10-K for FY2025, filed Nov 13, 2025As of the date hereof, we have engineered our first product, which is an enzyme for use in pharmaceutical API production of Ibuprofen.…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Jun 11, 2026
−$24.9KView ↗
- ▼ −62% (Loss)
- vs −$65.8K in Q3 FY2025
-
Apr 15, 2026
Formalized assignment of ibuprofen enzyme patent application rights
The CEO assigned the company rights to the patent application and related intellectual property, effective as of its filing date.
Sources
8-K, filed Apr 15, 2026
On April 9, 2026, Quantum Genesis AI Corp. (the “Company”) entered into a confirmatory Intellectual Property Assignment Agreement (the…View ↗
Loading...
